Chlamydia pneumoniae IgG titres and coronary heart disease:: prospective study and meta-analysis

被引:230
作者
Danesh, J [1 ]
Whincup, P
Walker, M
Lennon, L
Thomson, A
Appleby, P
Wong, YK
Bernardes-Silva, M
Ward, M
机构
[1] Univ Oxford, Clin Trial Serv Unit, Oxford OX2 6HE, England
[2] Univ Oxford, Epidemiol Studies Unit, Oxford OX2 6HE, England
[3] St George Hosp, Sch Med, Dept Publ Hlth Sci, London SW17 0RE, England
[4] UCL Royal Free & UCL Med Sch, Dept Populat Sci & Primary Care, London NW3 2PF, England
[5] Imperial Canc Res Fund, Epidemiol Unit, Oxford OX2 6HE, England
[6] Univ Southampton, Dept Cardiol, Southampton SO16 6YD, Hants, England
[7] Univ Southampton, Dept Mol Microbiol, Southampton SO16 6YD, Hants, England
来源
BRITISH MEDICAL JOURNAL | 2000年 / 321卷 / 7255期
关键词
D O I
10.1136/bmj.321.7255.208
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective To examine the association between coronary heart disease and serum markers of chronic Chlamydia pneumoniae infection. Design "Nested" case-control analysis in a prospective cohort study and an updated meta-analysis of previous relevant studies. Setting General practices in 18 towns in Britain. Participants Of the 5661 men aged 40-59 who provided blood samples during 1978-80, 496 men who died from coronary heart disease or had non-fatal myocardial infarction and 989 men who had not developed coronary heart disease by 1996 were included. Main outcome measures IgG serum antibodies to C pneumoniae in baseline samples; details of fatal and non-fatal coronary heart disease from medical records and death certificates. Results 200 (40%) of the 496 men with coronary heart disease were in the top third of C pneumoniae titres compared with 329 (33%) of the 989 controls. The corresponding odds ratio for coronary heart disease was 1.66 (95% confidence interval 1.25 to 2.21), which fell to 1.22 (0.82 to 1.82) after adjustment for smoking and indicators of socioeconomic status. No strong associations were observed between C pneumoniae IgG titres and blood lipid concentrations, blood pressure, or plasma homocysteine concentration. In aggregate, the present study and 14 other prospective studies of C pneumoniae IgG titres included 3169 cases, yielding a combined odds ratio of 1.15 (0.97 to 1.36), with no significant heterogeneity among the separate studies (chi(2) = 10.5, df = 14; P > 0.1). Conclusion This study, together with a meta-analysis of previous prospective studies, reliably excludes the existence of any strong association between C pneumoniae IgG titres and incident corollary heart disease. Further studies are required, however, to confirm or refute any modest association that may exist, particularly at younger ages.
引用
收藏
页码:208 / 212
页数:5
相关论文
共 25 条
[1]   Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection -: The azithromycin in coronary artery disease:: Elimination of myocardial infection with Chlamydia (ACADEMIC) study [J].
Anderson, JL ;
Muhlestein, JB ;
Carlquist, J ;
Allen, A ;
Trehan, S ;
Nielson, C ;
Hall, S ;
Brady, J ;
Egger, M ;
Horne, B ;
Lim, T .
CIRCULATION, 1999, 99 (12) :1540-1547
[2]   Chronic infections and coronary heart disease: is there a link? [J].
Danesh, J ;
Collins, R ;
Peto, R .
LANCET, 1997, 350 (9075) :430-436
[3]   Helicobacter pylori infection and early onset myocardial infarction:: case-control and sibling pairs study [J].
Danesh, J ;
Youngman, L ;
Clark, S ;
Parish, S ;
Peto, R ;
Collins, R .
BRITISH MEDICAL JOURNAL, 1999, 319 (7218) :1157-1162
[4]  
Danesh J, 1998, Expert Opin Investig Drugs, V7, P691, DOI 10.1517/13543784.7.5.691
[5]   The proatherogenic properties of lipoprotein(a) may be enhanced through the formation of circulating immune complexes containing Chlamydia pneumoniae-specific IgG antibodies [J].
Glader, CA ;
Boman, J ;
Saikku, P ;
Stenlund, H ;
Weinehall, L ;
Hallmanns, G ;
Dahlén, GH .
EUROPEAN HEART JOURNAL, 2000, 21 (08) :639-646
[6]  
Gupta S, 1997, CIRCULATION, V96, P404
[7]   Treatment with the antibiotic roxithromycin in patients with acute non-Q-wave coronary syndromes - The final report of the ROXIS study [J].
Gurfinkel, E ;
Bozovich, G ;
Beck, E ;
Testa, E ;
Livellara, B ;
Mautner, B .
EUROPEAN HEART JOURNAL, 1999, 20 (02) :121-127
[8]   Randomised trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS pilot study [J].
Gurfinkel, E ;
Bozovich, G ;
Daroca, A ;
Beck, E ;
Mautner, B .
LANCET, 1997, 350 (9075) :404-407
[9]  
Haider Agha W., 1999, Journal of the American College of Cardiology, V33, p314A
[10]  
Miettinen H, 1996, EUR HEART J, V17, P682